B7-H4標的治療薬：市場規模・対象患者集団・競合情勢・市場予測 (～2040年)

当レポートでは、米国、EU4カ国 (ドイツ、フランス、イタリア、スペイン)、英国、日本におけるB7-H4標的治療薬の市場を調査し、市場背景、市場動向、既存薬および新興薬の概要、競合情勢、市場シェア、患者数、市場規模の推移・予測、アンメットメディカルニーズ、市場アクセスと償還の動向などをまとめています。

主なハイライト

• 2027年には、米国がB7-H4市場全体で主要7カ国中最大のシェアを占めると予想されています。
• B7-H4は、腫瘍、炎症、自己免疫疾患、臓器移植など様々な疾患の治療における新規マーカーおよび治療標的として同定されています。現在、進行性の固形がんを対象に開発が進められており、開発の初期段階にあります。
• B7-H4標的治療薬は一般的に管理可能な副作用を示し、輸液反応は報告されていません。一般的な毒性には、疲労、好中球減少、貧血、神経障害、消化器症状などがあります。ADC関連の副作用は、既知の細胞毒性薬剤の副作用と一致します。
• 膀胱、卵巣、乳房の悪性腫瘍のような様々なタイプの腫瘍において、B7-H4指向性ADCは可能性を示しています。これらの腫瘍を有する患者は、特に標準治療に対して抵抗性を示したり、再発したりした場合、安全で効率的な標的治療に対するアンメットメードがまだかなり残っていることが多いです。
• 最近、米国FDAは2025年1月、トリプルネガティブ乳がん（TNBC）を含む、ヒト上皮成長因子受容体2（HER2）低値（IHC 1+またはIHC 2+/ISH-）またはHER2陰性（IHC 0）の進行性または転移性乳がん患者の治療薬として、emiltatug ledadotinにファストトラック指定（FTD）を追加承認しました。
• AstraZenecaは、独自のリンカーとトポイソメラーゼiペイロード技術を活用して一連のADCを開発しており、そのうちの1つはB7-H4を標的とする治験候補品で、puxitatug samrotecan（AZD8205）として知られています。2025年2月の発表によると、同社は2026年までにpuxitatug samrotecanの第I/II相試験の結果を期待しています。
• 2025年1月、Mersana Therapeuticsは、B7-H4を標的とするメルサナのADC候補であるDolasynthenのリード化合物であるemiltatug ledadotinの第I相用量漸増コホートおよびバックフィルコホートから得られた良好な初期臨床データを発表しました。
• 最近の情報によると、B7-H4とCD3を標的とする二重特異性抗体PF-07260437の臨床試験は、Pfizer 社内の経営判断により、第I相試験とともに終了しました。
• AstraZeneca、Pfizer（Seagen）、Mersana Therapeutics、GlaxoSmithKlineなど数社がさまざまな新薬を用いたB7-H4標的治療薬の開発に取り組んでいます。
• FPA-150はFive Prime Therapeuticsにより上皮性卵巣がんを対象に第i相で開発中でしたが、同社がAmgenにより買収されて以降、進展の報告はありません。
• B7-H4標的治療薬とPD-1、PD-L1、またはPARP阻害薬との併用は、相補的な抗腫瘍経路を活性化することによる耐性に対処するのに役立つ可能性があります。このような併用療法は、全体的な治療効果を改善し、耐性化を抑制する可能性があります。

B7-H4レポート：インサイト

• 標的患者集団
• 治療アプローチ
• パイプライン分析
• 市場規模および動向
• 既存および将来の市場機会

B7-H4レポート：主な強み

• 16年間の予測
• 主要7カ国のカバレッジ
• 主な競合薬
• 薬剤の使用量と主な市場予測の前提条件

B7-H4レポート：評価

• 現在の治療習慣
• アンメットニーズ
• パイプライン製品のプロファイル
• 市場の魅力
• 定性分析（SWOTおよびコンジョイント分析）

目次

第1章 重要な洞察

第2章 レポートイントロダクション

第3章 B7-H4：エグゼクティブサマリー

第4章 主要な出来事

第5章 疫学と市場予測の調査手法

第6章 主要7カ国におけるB7-H4市場：概要

• 市場シェア (％) の分布：治療薬別
• 市場シェア (％) の分布：適応症別

第7章 B7-H4：背景と概要

• さまざまな適応症におけるB7-H4阻害剤の可能性
• B7-H4阻害剤の臨床応用

第8章 B7-H4標的患者集団

• 主な調査結果
• 前提と根拠：主要7カ国
• 主要7カ国における疫学シナリオ
  • B7-H4阻害剤の特定の適応症における総症例数
  • B7-H4阻害剤の特定の適応症に対する治療適格患者数
  • B7-H4阻害剤の特定の適応症での実際の治療症例数

第9章 B7-H4の新興薬剤

• 主な競合薬
• Felmetatug vedotin: Pfizer (Seagen)
• Emiltatug ledadotin：Mersana Therapeutics

第10章 B7-H4：主要7カ国市場の分析

• 主な調査結果
• 市場見通し
• コンジョイント分析
• 主要な市場予測の前提条件
• 主要7カ国における市場規模：適応症別
• 主要7カ国における市場規模：治療薬別
• 米国
• EU4カ国・英国
• 日本

第11章 B7-H4：SWOT分析

第12章 B7-H4：KOL の見解

第13章 B7-H4：アンメットニーズ

第14章 B7-H4：市場アクセスと償還

第15章 付録

第16章 DelveInsightのサービス内容

第17章 免責事項

第18章 DelveInsightについて

List of Tables

• Table 1: Target Population in the 7MM (2020-2034)
• Table 2: Marketed Drug Key cross
• Table 3: Product 1, Clinical Trial Description, 2024
• Table 4: Product 2, Clinical Trial Description, 2024
• Table 5: Emerging Drug Key cross
• Table 6: Product 1, Clinical Trial Description, 2024
• Table 7: Product 2, Clinical Trial Description, 2024
• Table 8: Total B7-H4 Targeting Therapies Market Size in the 7MM (2020-2034)
• Table 9: B7-H4 Targeting Therapies Market Size by Therapies in the 7MM (2020-2034)
• Table 10: B7-H4 Targeting Therapies Market Size by Indication in the 7MM (2020-2034)
• Table 11: Total B7-H4 Targeting Therapies Market Size in the United States (2020-2034)
• Table 12: B7-H4 Targeting Therapies Market Size by Therapies in the United States (2020-2034)
• Table 13: Total B7-H4 Targeting Therapies Market Size in EU4 and the UK (2020-2034)
• Table 14: B7-H4 Targeting Therapies Market Size by Therapies in EU4 and the UK (2020-2034)
• Table 15: Total B7-H4 Targeting Therapies Market Size in Japan (2020-2034)
• Table 16: B7-H4 Targeting Therapies Market Size by Therapies in Japan (2020-2034)

List of Figures

• Figure 1: Target Population in the 7MM (2020-2034)
• Figure 2: Total B7-H4 Targeting Therapies Market Size in the 7MM (2020-2034)
• Figure 3: B7-H4 Targeting Therapies Market Size by Therapies in the 7MM (2020-2034)
• Figure 4: B7-H4 Targeting Therapies Market Size by Indication in the 7MM (2020-2034)
• Figure 5: Total B7-H4 Targeting Therapies Market Size in the United States (2020-2034)
• Figure 6: B7-H4 Targeting Therapies Market Size by Therapies in the United States (2020-2034)
• Figure 7: Total B7-H4 Targeting Therapies Market Size in EU4 and the UK (2020-2034)
• Figure 8: B7-H4 Targeting Therapies Market Size by Therapies in EU4 and the UK (2020-2034)
• Figure 9: Total B7-H4 Targeting Therapies Market Size in Japan (2020-2034)
• Figure 10: B7-H4 Targeting Therapies Market Size by Therapies in Japan (2020-2034)

Key Highlights:

• In 2027, the United States is expected to hold the largest share of the total B7-H4 market among the 7MM.
• B7-H4 has been identified as a novel marker and therapeutic target for treating various conditions, including tumors, inflammation, autoimmune diseases, and organ transplantation. Currently, it is being developed for advanced solid tumors and in an early stage of development.
• B7-H4-targeted therapies generally show manageable side effects, with no reported infusion reactions. Common toxicities include fatigue, neutropenia, anemia, neuropathy, and GI symptoms. ADC-related side effects match those of known cytotoxic agents.
• In a range of tumor types, such as bladder, ovarian, and breast malignancies, B7-H4-directed ADCs have shown potential. Patients with these tumors frequently still have substantial unmet requirements for safe and efficient targeted therapy, particularly if they have become resistant to or relapsed on standard-of-care treatments.
• Recently, In January 2025, US Food and Drug Administration (FDA) granted an additional Fast Track Designation (FTD) to emiltatug ledadotin for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 (HER2) low (IHC 1+ or IHC 2+/ISH-) or HER2-negative (IHC 0) disease, including triple-negative breast cancer (TNBC).
• AstraZeneca has leveraged its proprietary linker and topoisomerase I payload technologies to develop a series of internal ADCs, one of which is an investigational candidate targeting B7-H4, known as puxitatug samrotecan (AZD8205). As per February 2025 presentation, AstraZeneca is expecting Phase I/II results of puxitatug samrotecan by 2026.
• In January 2025, Mersana Therapeutics announced positive initial clinical data from the Phase I dose escalation and backfill cohorts for emiltatug ledadotin, Mersana's lead ADC candidate Dolasynthen targeting B7-H4.
• According to recent information, the clinical trial for PF-07260437, a bispecific antibody targeting B7-H4 and CD3, has been terminated by Pfizer due to an internal business decision, with the Phase I trial.
• Several companies, including AstraZeneca, Pfizer (Seagen), Mersana Therapeutics, GlaxoSmithKline, and others are engaged in the development of B7-H4 targeting therapies with a range of emerging drugs.
• FPA-150 was being developed by Five Prime Therapeutics in Phase I for Epithelial Ovarian Cancer. The company has not reported any development since its acquisition by Amgen.
• Combining B7-H4-targeted therapies with PD-1, PD-L1, or PARP inhibitors may help address resistance by activating complementary antitumor pathways. Such combinations could improve overall treatment efficacy and reduce the development of resistance.

DelveInsight's "B7-H4 - Target Population, Competitive Landscape, and Market Forecast - 2040" report delivers an in-depth understanding of the B7-H4, historical and Competitive Landscape as well as the B7-H4 targeted therapies market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The B7-H4 market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM B7-H4 market size from 2020 to 2040. The report also covers current B7-H4 treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2040

Understanding

B7-H4 Overview

The inhibitory molecule B7-H4, an important member of the B7 family, is abnormally expressed in tumors, inflammation, and autoimmune diseases. B7-H4 negatively regulates T cell immune response and promotes immune escape by inhibiting the proliferation, cytokine secretion, and cell cycle of T cells. Moreover, B7-H4 plays an extremely important role in tumorigenesis and tumor development including cell proliferation, invasion, metastasis, anti-apoptosis, etc. In addition, B7-H4 has other biological functions, such as protection against type 1 diabetes (T1D) and islet cell transplantation. Therefore, B7-H4 has been identified as a novel marker or a therapeutic target for the treatment of tumors, inflammation, autoimmune diseases, and organ transplantation. The transmembrane protein B7-H4 has emerged as an interesting therapeutic target in multiple solid tumors, with investigators mostly focusing on the development of antibody-drug conjugates (ADCs) aimed at the pathway.

However, overexpression of B7-H4 has been reported in many tumor types, including ovarian, lung, renal, breast, and gastric cancers. B7-H4 expression has been associated with increased tumor size, increased primary tumor classification, and/or diminished survival in these and other tumor types. Additionally, the protein has a role in tumorigenesis and tumor development via cell proliferation, invasion, metastasis, antiapoptosis, and other mechanisms.

B7-H4 Epidemiology

The B7-H4 epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total cases of selected indication for B7-H4, total eligible patient pool for B7-H4 in selected indication, total treated cases in selected indication for B7-H4 in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2040.

B7-H4 Drug Chapters

The drug chapter segment of the B7-H4 reports encloses a detailed analysis of late-stage (Phase II and Phase I) pipeline drugs. It also helps understand the B7-H4's clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

Felmetatug vedotin (SGN-B7H4V): Pfizer (Seagen)

Felmetatug vedotin is a novel investigational vedotin antibody-drug conjugate comprising a B7-H4-directed human monoclonal antibody conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine citrulline (mc-vc) linker. This vedotin linker-payload system has been clinically validated in multiple Food and Drug Administration-approved agents including brentuximab vedotin, enfortumab vedotin, and tisotumab vedotin. Currently, it is being developed in Phase I for the treatment of advanced solid tumors such as ovarian neoplasms, peritoneal neoplasms, triple-negative breast neoplasms, and others. Early results from Phase I study showed objective responses in 7 out of 28 breast cancer patients and 4 out of 20 ovarian cancer patients. Additionally, among 16 patients with endometrial cancer, 1 experienced a complete response.

In December 2023, Pfizer completed acquisition of all outstanding common stock of Seagen for USD 229 in cash per share, for a total enterprise value of approximately USD 43 billion.

Emiltatug ledadotin: Mersana Therapeutics

Emiltatug ledadotin is a B7-H4-directed Dolasynthen antibody-drug conjugate with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary payload with a controlled bystander effect. B7-H4 is overexpressed in a range of cancers, including breast, endometrial, and ovarian tumors. In 2022, Mersana initiated a multicenter Phase I trial to investigate the safety, tolerability, and anti-tumor activity of emiltatug ledadotin in patients with solid tumors, including in breast, endometrial, and ovarian cancers. The US FDA has granted fast track designation (FTD) to emiltatug ledadotin for the treatment of adult patients with advanced or metastatic triple-negative breast cancer. Currently, it is in Phase I of its developmental process.

In Phase I initial clinical trial results, emiltatug ledadotin was observed to be generally well tolerated, with no Grade 4 or 5 treatment-related adverse events (TRAEs) reported. The most common TRAEs of any grade across the entire patient population were transient aspartate aminotransferase (AST) increase (38% of patients), generally asymptomatic and reversible proteinuria (31%), generally low-grade nausea (29%) and low-grade fatigue (28%). The only Grade 3 TRAEs in >=5% or more of all patients were AST increase (14%) and proteinuria (9%).

B7-H4 Market Outlook

The market for B7-H4 targeting therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness of B7-H4, and the increasing number of B7-H4 targeting therapies that are under clinical trials.

The market outlook for B7-H4 targeted therapeutics is promising, driven by significant advancements in the development of innovative treatments for various cancers. Although no FDA-approved B7-H4 agents currently exist, preclinical and early-phase studies have demonstrated substantial potential, particularly with B7-H4 directed antibody-drug conjugate. Felmetatug vedotin, developed by Seagen, is a notable investigational antibody-drug conjugate comprising a B7-H4 directed human monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a clinically validated vedotin linker-payload system. It is in Phase I trials targeting advanced solid tumors, including ovarian and triple-negative breast cancers. Similarly, Mersana's emiltatug ledadotin, a B7-H4-directed Dolasynthen antibody-drug conjugate, features a target-optimized drug-to-antibody ratio and a controlled bystander effect. Emiltatug ledadotin is undergoing a multicenter Phase I trial for its safety and efficacy in breast, endometrial, and ovarian cancers, and has received FDA fast-track designation for advanced triple-negative breast cancer. Additionally, AstraZeneca's AZD8205 is in Phase I/IIa trials, targeting advanced solid tumors. These developments underscore the high potential of B7-H4-targeted therapies to address unmet needs in oncology, particularly for patients with refractory or relapsed cancers, positioning B7-H4 as a critical focus in the next generation of cancer treatment strategies.

Several key players, including AstraZeneca, Mersana Therapeutics, Pfizer (Seagen), GSK, and others, are involved in developing drugs for B7-H4 for various indications such as breast cancer, and non-small cell lung cancer. Overall, this is an exciting new class of agents with great potential for development. The maturation of current studies over the next few years will lead to a better understanding of B7-H4 and define their role in the therapy of cancer.

B7-H4 Drugs Uptake

This section focuses on the uptake rate of potential emerging B7-H4 expected to be launched in the market during -2040.

B7-H4 Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

The presence of numerous drugs under different stages is expected to generate immense opportunity for B7-H4 market growth over the forecast period.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for B7-H4 therapies.

KOL Views

To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on B7-H4' evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight's analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Johns Hopkins Sidney Kimmel Cancer Center, UCSF Health, Memorial Sloan Kettering Cancer Center, and others.

Their opinion helps understand and validate current and emerging therapy treatment patterns or B7-H4 market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third party organizations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Key Updates on B7-H4

• In May 2024, Mersana Therapeutics announced that the maximum tolerated dose has not yet been established in the Phase I clinical trial of emiltatug ledadotin. Enrollment in dose escalation and backfill cohorts is continuing in parallel, with initial clinical data and the initiation of expansion expected in the second half of 2024.
• In April 2024, NextCure announced the presentation of new preclinical data on LNCB74, a B7-H4 targeting antibody-drug conjugate developed in partnership with LigaChem Biosciences (LCB), formerly LegoChem Biosciences, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego. The poster presentation highlights LNBC74's promising preclinical safety and anti-tumor activity.
• In October 2023, GSK and Hansoh Pharma announced that they have entered into an exclusive license agreement for HS-20089, a B7-H4 targeted antibody drug currently in Phase I (NCT05263479) clinical trials in China. Under the agreement, GSK will obtain exclusive worldwide rights (excluding China's mainland, Hong Kong, Macau, and Taiwan) to progress the development and commercialization of HS-20089.
• In ASCO 2023, Mersana Therapeutics presented the trial design of a Phase Ib trial of a B7-H4 targeted ADC in breast, endometrial, and ovarian cancers.
• Although B7-H4 targeted therapeutics are still in the early stages of development and no FDA-approved drug exists yet, preclinical and early-phase studies have validated the initial interest in this pathway. Currently, there are several drugs in the early phase of clinical trials, including AZD8205, emiltatug ledadotin, felmetatug vedotin, GSK5733584, LNCB74, and others.

The abstract list is not exhaustive, will be provided in the final report

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of the B7-H4, explaining its mechanism, and therapies (emerging).
• Comprehensive insight into the Competitive Landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the B7-H4 market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM B7-H4 market.

B7-H4 Report Insights

• B7-H4 Targeted Patient Pool
• Therapeutic Approaches
• B7-H4 Pipeline Analysis
• B7-H4 Market Size and Trends
• Existing and Future Market Opportunity

B7-H4 Report Key Strengths

• 16 years Forecast
• The 7MM Coverage
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

B7-H4 Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint analysis)

Key Questions:

• What was the B7-H4 total market size, the market size by therapies, market share (%) distribution, and what would it look like in 2040? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2040?
• Which is the most lucrative market for B7-H4?
• What are the risks, burdens, and unmet needs of treatment with B7-H4 based therapies? What will be the growth opportunities across the 7MM for the patient population of B7-H4 based therapies?
• What are the key factors hampering the growth of the B7-H4 market?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for B7-H4?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to buy:

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the B7-H4 Market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of B7-H4

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. B7-H4 Market Overview at a Glance in the 7MM

• 6.1. Market Share (%) Distribution by Therapies in 2027
• 6.2. Market Share (%) Distribution by Therapies in 2040
• 6.3. Market Share (%) Distribution by Indications in 2027
• 6.4. Market Share (%) Distribution by Indications in 2040

7. B7-H4: Background and Overview

• 7.1. Introduction
• 7.2. Potential of B7-H4 Inhibitor in Different Indications
• 7.3. Clinical Applications of B7-H4 Inhibitor

8. B7-H4 Target Patient Pool

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: 7MM
• 8.3. Epidemiology Scenario in the 7MM
  • 8.3.1. Total Cases of Selected Indication for B7-H4 in the 7MM
  • 8.3.2. Total Eligible Patient Pool for B7-H4 in Selected Indication in the 7MM
  • 8.3.3. Total Treatable Cases in Selected Indication for B7-H4 in the 7MM

9. B7-H4 Emerging Therapies

• 9.1. Key Competitors
• 9.2. Felmetatug vedotin: Pfizer (Seagen)
  • 9.2.1. Product Description
  • 9.2.2. Other developmental activities
  • 9.2.3. Clinical development
  • 9.2.4. Safety and efficacy
• 9.3. Emiltatug ledadotin: Mersana Therapeutics
  • 9.3.1. Product Description
  • 9.3.2. Other developmental activities
  • 9.3.3. Clinical development
  • 9.3.4. Safety and efficacy

10. B7-H4: Seven Major Market Analysis

• 10.1. Key Findings
• 10.2. Market Outlook
• 10.3. Conjoint Analysis
• 10.4. Key Market Forecast Assumptions
  • 10.4.1. Cost Assumptions and Rebates
  • 10.4.2. Pricing Trends
  • 10.4.3. Analogue Assessment
  • 10.4.4. Launch Year and Therapy Uptakes
• 10.5. Total Market Size by Indication in the 7MM
• 10.6. Total Market Size by therapies in the 7MM
• 10.7. The United States
  • 10.7.1. Total Market Size of B7-H4 in the United States
  • 10.7.2. Market Size of B7-H4 by Indication in the United States
  • 10.7.3. Market Size of B7-H4 by Therapies in the United States
• 10.8. EU4 and the UK
  • 10.8.1. Total Market Size of B7-H4 in EU4 and the UK
  • 10.8.2. Market Size of B7-H4 by Indication in EU4 and the UK
  • 10.8.3. Market Size of B7-H4 by Therapies in EU4 and the UK
• 10.9. Japan
  • 10.9.1. Total Market Size of B7-H4 in Japan
  • 10.9.2. Market Size of B7-H4 by Indication in Japan
  • 10.9.3. Market Size of B7-H4 by Therapies in Japan

11. SWOT Analysis of B7-H4

12. KOL Views of B7-H4

13. Unmet Needs of B7-H4

14. Market Access and Reimbursement of B7-H4

15. Appendix

• 15.1. Bibliography
• 15.2. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight